Blepharitis

Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis

Retrieved on: 
Tuesday, March 5, 2024
Education, Inflammation, FDA, Irritation, MITES, Blepharitis, OD, Patient, Disease, Eyelid, Diagnosis, Science, Infestation, Human, TARS, Pharmaceutical industry

“Mite Party” is designed to elevate consumer awareness of Demodex blepharitis through relatable messaging and compelling visuals to encourage patients who may have Demodex blepharitis to seek out an eye care provider for screening.

Key Points: 
  • “Mite Party” is designed to elevate consumer awareness of Demodex blepharitis through relatable messaging and compelling visuals to encourage patients who may have Demodex blepharitis to seek out an eye care provider for screening.
  • “We are committed to increasing Demodex blepharitis education and awareness so that patients more effectively understand their disease and are motivated to seek treatment,” said Aziz Mottiwala, Chief Commercial Officer of Tarsus.
  • We look forward to advancing this novel campaign with the goal of helping as many patients with Demodex blepharitis as possible.”
    Demodex blepharitis occurs when Demodex mites – the most common ectoparasites found on humans – overpopulate on the eyelids.
  • “Mite Party” will officially launch on the XDEMVY Facebook page (@xdemvyrx) with a live event designed to “break up the mite parties” on Demodex blepharitis patients’ eyelids.

Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement

Retrieved on: 
Tuesday, January 16, 2024
Ageing, Regeneron Pharmaceuticals, Mouth ulcer, Patient, European, Conjunctivitis, Eosinophilia, Foot, Blepharitis, Keratitis, Walking, Aes, Skin, Food, Safety, Human, Inflammation, FDA, Physician, Bleeding, Atopic dermatitis, International development, Pharmaceutical industry

TARRYTOWN, N.Y. and PARIS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has updated the label for Dupixent® (dupilumab) in atopic dermatitis, adding efficacy and safety data for patients aged 12 years and older with atopic dermatitis with uncontrolled moderate-to-severe hand and/or foot involvement. These Phase 3 data are from the first and only trial evaluating a biologic specifically for this difficult-to-treat population and have also been added to the Dupixent label in the European Union, with regulatory submissions underway in additional countries.

Key Points: 
  • These Phase 3 data are from the first and only trial evaluating a biologic specifically for this difficult-to-treat population and have also been added to the Dupixent label in the European Union, with regulatory submissions underway in additional countries.
  • “Having these data added for this difficult-to-treat population is important for physicians looking for tools to treat these patients and reinforces the already well-established efficacy and safety of Dupixent in atopic dermatitis overall.”
    The label update is based on data from the Phase 3 LIBERTY-AD-HAFT trial.
  • In the trial, patients received Dupixent (n=67) every two weeks (adults 300 mg, adolescents 200 mg or 300 mg based on body weight) or placebo (n=66).
  • Most common adverse events (AEs) observed with Dupixent (≥1%) in atopic dermatitis include injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye and eosinophilia.

NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network

Retrieved on: 
Tuesday, January 9, 2024
Medical Supplies, Marketing, Communications, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Optical, NBY, European, General counsel, NovaBay Pharmaceuticals, Blepharitis, Eyelash, Irritation, Sale, Hypochlorous acid, Inflammation, Red, Eyelid, Cosmetics

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced an agreement for the sale and marketing of Avenova®-branded products by Sonoma in the European Union.

Key Points: 
  • NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced an agreement for the sale and marketing of Avenova®-branded products by Sonoma in the European Union.
  • This agreement brings together NovaBay’s deep knowledge of eye care reflected in its Avenova brand with Sonoma’s expertise in distributing hypochlorous acid products overseas.
  • “Sonoma has built a strong and growing presence in the European Union through a network of distributors and direct sales.
  • “The EU market is comparable in size to the U.S., giving NovaBay the opportunity to double its sales of Avenova.

Lunovus Enhances Its Eyecare Software and Service Solutions with Acquisition of Diamond Studios

Retrieved on: 
Friday, November 17, 2023
Health, Technology, Optical, Health Technology, Software, Diamond, Miele, Tom Denney, Macular degeneration, Patient, OTC, Diabetes, Partnership, Video game, Blepharitis

Lunovus LLC, a physician-owned pioneer in the eyecare industry, known for its advanced medical software and eye care supplementation solutions, has officially acquired Diamond Studios, a distinguished software development and media firm.

Key Points: 
  • Lunovus LLC, a physician-owned pioneer in the eyecare industry, known for its advanced medical software and eye care supplementation solutions, has officially acquired Diamond Studios, a distinguished software development and media firm.
  • As part of its commitment to excellence, Lunovus is channeling resources into Diamond Studios to expand its range of services and product offerings.
  • Over the past five years, Diamond Studios has played a critical role in developing the Lunovus Doc2Home platform.
  • Embracing the future, Lunovus LLC and Diamond Studios share a key commitment to innovation, poised to deliver top-tier solutions in the dynamic fields of software development and media.

HealthWell Foundation Launches Fund to Assist People Living with Blepharitis

Retrieved on: 
Tuesday, September 26, 2023
Insurance, University, Inflammation, Blepharitis, Telecanthus, Eyelid, MD, Patient, Gland, University of California, Berkeley, Health insurance, Pacific Ocean

GERMANTOWN, Md., Sept. 26, 2023 /PRNewswire/ -- The HealthWell Foundation®, an independent non-profit that provides a financial lifeline for inadequately insured Americans, has opened a new fund to provide financial assistance to individuals living with blepharitis. Through the fund, HealthWell will provide up to $3,500 in medication copayment or insurance premium assistance to eligible patients with annual household incomes up to 500 percent of the federal poverty level for the management of their condition.

Key Points: 
  • GERMANTOWN, Md., Sept. 26, 2023 /PRNewswire/ -- The HealthWell Foundation®, an independent non-profit that provides a financial lifeline for inadequately insured Americans, has opened a new fund to provide financial assistance to individuals living with blepharitis.
  • Blepharitis is inflammation of the eyelid which causes the edges of the eyelid to become red or dark in color, swollen, and scaly.
  • There are two types of blepharitis: anterior blepharitis (occurs on the eyelid's front exterior) and posterior blepharitis (meibomian glands under the eyelid become blocked so oil release is impaired and they can become infected).
  • The HealthWell Foundation recognizes the hardship those living with blepharitis endure and we look forward to providing financial assistance so patients can start and continue treatment if needed."

Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis

Retrieved on: 
Thursday, August 24, 2023
Pharmacy, TARS, Inflammation, Doctor of Philosophy, Science, Blepharitis, MD, Patient, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Full, Disease, Pharmaceutical industry, Demodex

IRVINE, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, announced that XDEMVY™ (lotilaner ophthalmic solution) 0.25% is now available at pharmacies nationwide for prescription. The U.S. Food and Drug Administration (FDA) approved XDEMVY on July 24, 2023, for the treatment of Demodex blepharitis.

Key Points: 
  • The U.S. Food and Drug Administration (FDA) approved XDEMVY on July 24, 2023, for the treatment of Demodex blepharitis.
  • “We are delighted that within weeks of FDA approval, XDEMVY is now available to millions of patients with Demodex blepharitis,” said Bobak Azamian, MD, PhD, Chief Executive Officer and Chairman of Tarsus.
  • Demodex blepharitis is characterized by redness, inflammation, missing or misdirected eyelashes, itching along the eyelid base, and the presence of collarettes.
  • To learn more about XDEMVY, including the Full Prescribing Information, please visit xdemvy.com and follow XDEMVY on Facebook and Instagram .

AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test

Retrieved on: 
Tuesday, August 1, 2023
Software, Research, Pharmaceutical, Optical, Oncology, Medical Devices, Technology, Health Technology, Science, COVID-19, Biotechnology, Health, Infection, Patent, University, University of Houston, Urine, ECS, SAR, Serum, QSOX1, Survival, Telecanthus, Tears, Cancer, EIS, SARS, Bladder cancer, Brain, Attention, COVID, Provisional application, IP, Biomarker, Person, Lacritin, Plasma, Ebola virus disease treatment research, Eye, Diagnosis, Immunoglobulin E, FDA, A-DNA, Virus, Tearing, Fentanyl, Treatment, SARS-CoV-2, Vaccine, Natural rubber, Medical imaging, Lactoferrin, Blepharitis

The first patent application recently allowed relates to COVID and other neutralizing antibody (Nab) testing and treatment.

Key Points: 
  • The first patent application recently allowed relates to COVID and other neutralizing antibody (Nab) testing and treatment.
  • The allowance confirms that AXIM was a pioneer in developing a rapid point of care Nab test and its novelty.
  • Additionally, the company was notified by the USPTO of a second patent allowance for systems and methods for rapid diagnostic for various cancers.
  • 1 Utility Patent Application
    The invention relates to a Rapid Point of Care test for Human Monomeric Lacritin.

FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis

Retrieved on: 
Tuesday, July 25, 2023
Parasitism, Loss, Refractive surgery, Therapy, Eyelash, OD, Overalls, Eye, Skin, NewYork-Presbyterian Hospital, Medicine, TARS, Inflammation, Doctor of Philosophy, Associate, Science, Blepharitis, Eyelid, MD, Patient, Crust punk, Irritation, Webcast, Weill Cornell Medicine, MITES, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Disease, Egg, Pharmaceutical industry, Demodex, Ophthalmology

IRVINE, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that the U.S. Food and Drug Administration (FDA) approved XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis. XDEMVY, formerly known as TP-03, is the first and only FDA approved treatment to directly target Demodex mites, the root cause of Demodex blepharitis.

Key Points: 
  • XDEMVY, formerly known as TP-03, is the first and only FDA approved treatment to directly target Demodex mites, the root cause of Demodex blepharitis.
  • Patients with Demodex blepharitis were randomized to either XDEMVY or vehicle at a 1:1 ratio and dosed twice daily in each eye over the course of 6 weeks.
  • Demodex blepharitis is characterized by redness, inflammation, missing or misdirected eyelashes, horizontal itching along the eyelid base and the presence of collarettes.
  • After the live webcast, the event will remain archived on the Tarsus website for at least 90 days.

LianBio Completes Enrollment in Pivotal Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

Retrieved on: 
Thursday, June 8, 2023
Eyelash, LIBRA, Quality of life, Inflammation, Erythema, Patient, Blepharitis, MITES, Safety, Disease, Pharmaceutical industry, Demodex

SHANGHAI, China and PRINCETON, N.J., June 08, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the completion of enrollment in the Phase 3 LIBRA clinical trial of TP-03 in Chinese patients with Demodex blepharitis.

Key Points: 
  • “LianBio is committed to bringing a safe and effective treatment option to the tens of millions of patients living with Demodex blepharitis in China,” said Yizhe Wang, Ph.D., Chief Executive Officer of LianBio.
  • “Although patients with Demodex blepharitis experience significant impact to quality of life, today there are no available treatments that address the underlying cause of their disease.
  • LIBRA is a Phase 3 multicenter, double-blind, randomized, vehicle-controlled registrational study designed to evaluate the efficacy and safety of TP-03 in Chinese adult patients with Demodex blepharitis, with an open-label pharmacokinetics sub-study.
  • LianBio expects to report topline results from the LIBRA trial in the fourth quarter of 2023.

Tarsus Launches “Don’t Freak Out. Get Checked Out.” Campaign During Healthy Vision Month to Encourage Patients with Demodex Blepharitis to Visit Eye Care Providers

Retrieved on: 
Monday, May 8, 2023
Human, Arm, Eyelash, Education, OD, Cataract, Attention, TARS, Inflammation, Science, Blepharitis, Slit lamp, Eyelid, MD, Patient, Infestation, Red, Disease, Pharmaceutical industry, Telescopic sight, Nursing, Cosmetics, Demodex

IRVINE, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the launch of “Don’t Freak Out. Get Checked Out.”, a disease education campaign designed to encourage patients who may have Demodex blepharitis to visit their eye care provider for an eyelid check. In support of Healthy Vision Month in May, the first of its kind campaign is designed to support patients on their journey to identify the cause of their eyelid discomfort.

Key Points: 
  • Get Checked Out.”, a disease education campaign designed to encourage patients who may have Demodex blepharitis to visit their eye care provider for an eyelid check.
  • In support of Healthy Vision Month in May, the first of its kind campaign is designed to support patients on their journey to identify the cause of their eyelid discomfort.
  • Demodex blepharitis is caused by an overpopulation of Demodex mites, the most common ectoparasites found in humans.
  • “Demodex blepharitis patients often complain of severe discomfort and can be extremely conscious of how their eyes feel all day.